The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 05, 2013

Filed:

May. 09, 2012
Applicants:

Eleftherios P. Diamandis, Toronto, CA;

Chan-kyung Jane Cho, Toronto, CA;

Eduardo Martinez Morillo, Toronto, CA;

Inventors:

Eleftherios P. Diamandis, Toronto, CA;

Chan-Kyung Jane Cho, Toronto, CA;

Eduardo Martinez Morillo, Toronto, CA;

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/573 (2006.01); A61K 35/50 (2006.01); A61K 35/14 (2006.01); A61K 35/413 (2006.01); A61K 38/00 (2006.01); A61P 25/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.


Find Patent Forward Citations

Loading…